ALTITUDE-AD: Use of a Validated Plasma pTau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Early Alzheimer&#39;s Disease

sabirnetug IV (ACU193 IV) - Acumen Pharma

https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-003870.html

H Todd Feaster1; Karen Sundell1; Maddelyn Hyland1; Gopalan Sethuraman1; Vladimir Skljarevski1; June Kaplow1; Robert A. Dean1; Jasna Jerecic1; Eric Siemers1

Mar 8, 2025